SBIR/STTR Research Award

Development of an ophthalmic diagnostic probe for neurodegenerativedisorders

Award identifier 8557be0cc70f013bef0bf136e9fb5ae13b0c7a51b020c184d6f6bddaaff194efAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,859,082

Program and phase

SBIR · Phase II

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Amydis Diagnostics Inc.
Proposal award date
2016-09-30
Contract end date
2018-05-31
UEI
LCXNBB1KM9K9
Solicitation number
PA15-269
Topic code
NIA

Research abstract

Project Summary Deposition of amyloid plaques in the brain represents a universal feature Alzheimer s disease pathology and precedes clinical symptoms by several years Currently diagnosis of amyloid associated dementias in individuals showing symptoms of cognitive decline is extremely difficult requiring multiple modes of testing over months to years Early pre symptomatic diagnosis is even more challenging if not impossible with currently available technology A non invasive method for diagnosing Alzheimer s disease is greatly needed We will further evaluate the use of AMDX a novel fluorescent probe that can label amyloids in tissue as a diagnostic for Alzheimer s disease AMDX has been shown to fluorescently label AD related deposits in vivo Importantly this probe has also been shown to effectively image amyloid deposits in the retina of AD mice following both topical and intravenous dosing The properties of AMDX are ideal for its development as a topical diagnostic probe for AD The studies outlined in this proposal advance AMDX to the Pre IND stage The synthesis of AMDX will be optimized through dedicated process development activities A formulation effective for topical administration in humans will be developed along with in vivo evaluation of diagnostic efficacy in two species of animals Further the retinal images obtained throughout formulation development will be utilized to develop a method to quantify the number size and intensity of amyloid deposits Together the aims of this proposal will result in an optimized diagnostic product capable of imaging AD in the retina The diagnostic product will be advanced to the point of being ready for IND enabling Toxicology studies Project Narrative Alzheimer s disease is characterized by the deposition of insoluble protein aggregates in the brain that are referred to as amyloids Recently these amyloids have been identified in retinal tissue in diseased individuals The proposed research aims advance a topical diagnostic to image amyloid deposits

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

11 SBIR/STTR records share this UEI (2015–2025). Reported award amounts total $16,496,188. Reported amounts are not federal obligations.

Phases: Phase II, Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.